Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.71 - $29.94
Previous CloseN/A
Volume97.81K
Average Volume (3M)2.69M
Market Cap
$2.07B
Enterprise Value$1.05B
Total Cash (Recent Filing)$173.42M
Total Debt (Recent Filing)$50.91M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 11, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding86,091,450
10 Day Avg. Volume3,084,437
30 Day Avg. Volume2,693,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue54.30
Enterprise Value/Gross Profit77.18
Enterprise Value/Ebitda-8.48
Forecast
1Y Price Target
$36.89Price Target Upside52.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe upcoming October R&D Day is expected to spotlight the L606 program, with new long-term data and Phase 3 trial details that could unlock value and highlight Liquidia’s underappreciated clinical development depth.
Financial PerformanceCash-flow positivity and profitability may arrive sooner than expected, reflecting disciplined cost management, stable SG&A, and improving refill and adherence patterns.
Sales PerformanceYutrepia sales appear positioned for a strong first full quarter, supported by robust prescription trends, favorable payer dynamics, and high conversion rates.
Bears Say
Financial ConstraintsLiquidia has approximately 1.1 years of cash left, indicating potential financial constraints in the near future.
Investor SentimentThe high short interest of 27.2% suggests that there is a significant amount of skepticism or bearish sentiment among investors about the stock.
Market CompetitionLiquidia Technologies faces two major overhangs: a 5-year patent battle with UTHR and competition from INSM’s once-daily inhaled treprostinil.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $9.71 and its highest was $29.94 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $2.07B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 11, 2025 which is in 32 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 12, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.432 by -$0.058.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -0.4.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 86,091,450 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.432. Following the earnings report the stock price went up 13.679%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.89 (52.12% Upside)
$36.89 (52.12% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 347.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.51%
12-Months-Change
Fundamentals
Return on Equity
-363.16%
Trailing 12-Months
Asset Growth
45.13%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong start for YUTREPIA, with impressive prescription numbers and conversion rates, positive study results, and a solid financial position. However, challenges with market entry blocks and reliance on channel inventory for initial revenue were noted.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$36.89
▲(52.12% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
22.94% Insiders
7.02% Mutual Funds
38.11% Other Institutional Investors
23.95% Public Companies and
Individual Investors